Abstract
Anticancer enzyme / prodrug approaches to therapy are designed to activate prodrugs specifically at tumor loci, to achieve antitumor responses with minimal toxicity. The equivocal success of these approaches thus far has led to searches for more efficient combinations. This mini-review evaluates and compares characteristics of seven selected enzyme / prodrug combinations, and discusses goals for future development of effective combinations.
Keywords: enzyme prodrug therapy, hsv-tk gcv, Herves Simplex Virus-Thymidine Kinase Ganciclovir, cd 5-fc, cytosine deaminase 5-fluorocytosine, pnpase 2-f-araa, purine nucleoside phosphorylase 2-fluoroarabinosyl adenine
Current Medicinal Chemistry - Anti-Cancer Agents
Title: Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy
Volume: 5 Issue: 2
Author(s): K. Jin Yoon, Philip M. Potter and Mary K. Danks
Affiliation:
Keywords: enzyme prodrug therapy, hsv-tk gcv, Herves Simplex Virus-Thymidine Kinase Ganciclovir, cd 5-fc, cytosine deaminase 5-fluorocytosine, pnpase 2-f-araa, purine nucleoside phosphorylase 2-fluoroarabinosyl adenine
Abstract: Anticancer enzyme / prodrug approaches to therapy are designed to activate prodrugs specifically at tumor loci, to achieve antitumor responses with minimal toxicity. The equivocal success of these approaches thus far has led to searches for more efficient combinations. This mini-review evaluates and compares characteristics of seven selected enzyme / prodrug combinations, and discusses goals for future development of effective combinations.
Export Options
About this article
Cite this article as:
Yoon Jin K., Potter M. Philip and Danks K. Mary, Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy, Current Medicinal Chemistry - Anti-Cancer Agents 2005; 5 (2) . https://dx.doi.org/10.2174/1568011053174837
DOI https://dx.doi.org/10.2174/1568011053174837 |
Print ISSN 1568-0118 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5968 |
Related Articles
-
Glycoconjugates in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research
Current Medicinal Chemistry Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Inhibitory Effect of Ebselen on Cerebral Acetylcholinesterase Activity In Vitro: Kinetics and Reversibility of Inhibition
Current Pharmaceutical Design Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research MAP Kinase Pathways in Neuronal Cell Death
CNS & Neurological Disorders - Drug Targets Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer
Current Medicinal Chemistry Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Development of Casein Kinase 1 Inhibitors
Current Medicinal Chemistry Cellomics as Integrative Omics for Cancer
Current Proteomics The Chemistry of Bioactive Diterpenes
Current Organic Chemistry The Impact of Proteomics in the Understanding of the Molecular Basis of Paclitaxel-Resistance in Ovarian Tumors
Current Cancer Drug Targets Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets The Medicinal Chemistry of Peptides
Current Medicinal Chemistry